Publications by authors named "Elizabeth D Lightbody"

Claim this Profile
S
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.
Elizabeth D Lightbody, Romanos Sklavenitis-Pistofidis, Ting Wu, Junko Tsuji, Danielle T Firer

Nat Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data.
Ruitong Li, Jean-Baptiste Alberge, Tina Keshavarzian, Junko Tsuji, Johan Gustafsson, Elizabeth D Lightbody

Brief Bioinform· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q.
Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, Junko Tsuji, Jean-Baptiste Alberge

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of multiple myeloma and its precursor conditions.
Jean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, Tim H H Coorens, Elizabeth D Lightbody

Nat Genet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum free light chains in a racially diverse population including African Americans and populations from South Africa.
Luca Bertamini, Jean-Baptiste Alberge, David J Lee, Habib El-Khoury, Sungjae Kim, Elizabeth D Lightbody

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, Ting Wu, Nicholas Tsakmaklis, Elizabeth D Lightbody

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D Lightbody

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.
Sabrin Tahri, Sara Piccinelli, Nang Kham Su, Luisa Lampe, Han Dong, Elizabeth D Lightbody

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D Lightbody

medRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, Junko Tsuji, Michelle P Aranha

bioRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Noor Shakfa, Deyang Li, Gwenaelle Conseil, Elizabeth D Lightbody, Juliette Wilson-Sanchez

J Immunother Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Ankit K Dutta, Jean-Baptiste Alberge, Elizabeth D Lightbody, Cody J Boehner, Andrew Dunford

Cancer Discov· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala, Elizabeth D Lightbody

Cancer Cell· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
Habib El-Khoury, David J Lee, Jean-Baptiste Alberge, Robert Redd, Christian J Cea-Curry, Elizabeth D Lightbody

Lancet Haematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
Ankit K Dutta, Jean-Baptiste Alberge, Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Gad Getz

Nat Rev Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass cytometry staining for human bone marrow clinical samples.
Margaret Hallisey, Jenna Dennis, Charlotte Abrecht, Romanos Sklavenitis Pistofidis, Abigail N Schork, Elizabeth D Lightbody

STAR Protoc· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Hong Yue, Federico Ferrari, Robert A Redd, Elizabeth D Lightbody

Cancer Cell· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications.
Asish Dasgupta, Kuang-Hueih Chen, Danchen Wu, Victoria Hoskin, Jeffrey Mewburn, Elizabeth D Lightbody

FASEB J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunofluorescence Labeling of Nuclear Receptor Expression in Formalin-Fixed, Paraffin-Embedded Tissue.
Elizabeth D Lightbody, Christopher J B Nicol

Methods Mol Biol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial Cell-Targeted Deletion of PPAR Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue.
Taro E Akiyama, Graham E Skelhorne-Gross, Elizabeth D Lightbody, Rachel E Rubino, Jia Yue Shi

J Pharmacol Exp Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel prognostic and predictive microRNA targets for triple-negative breast cancer.
Gulisa Turashvili, Elizabeth D Lightbody, Kathrin Tyryshkin, Sandip K SenGupta, Bruce E Elliott

FASEB J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis